Metabolic obesity phenotypes and adverse pregnancy outcomes: a National Cross-Sectional study
Tongxin Wang1, Yuehua Tang1, Qimeng Zhu1
1Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China; Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong 250021, China; Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong 250021, China; "Chuangxin China" Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, China; Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong 250021, China; Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, Shandong 250021, China.
Purpose:
To evaluate the association between metabolic obesity phenotypes and adverse pregnancy outcomes.
Methods:
This was a population-based cross-sectional study utilizing data from the Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS) from 2016 to 2018, including 2,065,701 delivery hospitalizations. Women were categorized into four metabolic obesity phenotypes based on obesity status and the metabolic abnormalities (hypertension, hyperlipidemia, and hyperglycemia/type 2 diabetes): metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO) and metabolically unhealthy obese (MUO). Multivariable logistic regression was used to assess the relationship between metabolic obesity phenotypes and adverse pregnancy outcomes.
Results:
Compared to the MHNO group, both MUNO and MUO women had significantly higher odds of adverse maternal outcomes (including postpartum hemorrhage, hypertensive complications, cesarean delivery, and hysterectomy) and adverse neonatal outcomes (including preterm birth, fetal growth restriction, large for gestational age, fetal death, and congenital anomalies). An increasing number of metabolic abnormalities was associated with progressively higher odds of adverse maternal and neonatal outcomes, independent of obesity status.
Conclusion:
The presence of metabolic abnormalities, with or without obesity, was associated with higher odds of adverse pregnancy outcomes. Our study highlights the importance of early metabolic screening and tailored interventions in routine prenatal care to improve pregnancy outcomes.
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational

